Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials

DiazGranados, Carlos A.; Denis, Martine; Plotkin, Stanley А.

doi:10.1016/j.vaccine.2012.10.084

Cited by 148 publications

(123 citation statements)

References 57 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…The protection in children (range 20–77%) and in healthy adults (range 50–59%) seen in the tropics and subtropics was comparable with that seen in developed countries 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74. Vaccine protection studies from the tropics and subtropics faced certain limitations.…”

Section: Discussionsupporting

confidence: 57%

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Hirve

Lambach

Paget

et al. 2016

Influenza Resp Viruses

View full text Add to dashboard Cite

AimThe evidence needed for tropical countries to take informed decisions on influenza vaccination is scarce. This article reviews policy, availability, use and effectiveness of seasonal influenza vaccine in tropical and subtropical countries.MethodGlobal health databases were searched in three thematic areas – policy, availability and protective benefits in the context of human seasonal influenza vaccine in the tropics and subtropics. We excluded studies on monovalent pandemic influenza vaccine, vaccine safety, immunogenicity and uptake, and disease burden.ResultsSeventy‐four countries in the tropics and subtropics representing 60% of the world's population did not have a national vaccination policy against seasonal influenza. Thirty‐eight countries used the Northern Hemisphere and 21 countries the Southern Hemisphere formulation. Forty‐six countries targeted children and 57 targeted the elderly; though, the age cut‐offs varied. Influenza vaccine supply increased twofold in recent years. However, coverage remained lower than five per 1000 population. Vaccine protection against laboratory‐confirmed influenza in the tropics ranged from 0% to 42% in the elderly, 20–77% in children and 50–59% in healthy adults. Vaccinating pregnant women against seasonal influenza prevented laboratory‐confirmed influenza in both mothers (50%) and their infants <6 months (49–63%).ConclusionGuidelines on vaccine composition, priority risk groups and vaccine availability varied widely. The evidence on vaccine protection was scarce. Countries in the tropics and subtropics need to strengthen and expand their evidence‐base required for making informed decisions on influenza vaccine introduction and expansion, and how much benefit to expect.

show abstract

Section: Discussionsupporting

confidence: 57%

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Hirve

Lambach

Paget

et al. 2016

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…As mentioned by Quinn et al [13], recent evidence suggests that cross-protection of TIV to the opposite influenza B virus exists, potentially diminishing the impact of QIV significantly [43,44]. Our review shows that the majority of studies included cross-protection in their analyses.…”

Section: Expert Commentarymentioning

confidence: 66%

“…Therefore, the vaccine efficacy against influenza A is not explicitly taken into consideration in this review. With regard to vaccine efficacy against influenza B, most studies used data from published meta-analysis by Tricco et al [43] or DiazGranados et al [44], while two studies [20,31] adopted the vaccine efficacy reported for the US vaccination program by Reed et al [42]. Two studies did not differentiate between vaccine efficacy against influenza A and influenza B [24,29].…”

Section: Characteristics Of the Vaccination Programs And Vaccinesmentioning

confidence: 99%

“…Our review shows that the majority of studies included cross-protection in their analyses. Most studies referred to systematic reviews by Tricco et al [43] and DiazGranados et al [44], estimating that the vaccine efficacy of TIV against the non-included B virus strain is 65-70% of the matched efficacy. Studies on single influenza seasons confirmed the finding of cross-protection during the 2012-2013 season in the US and Canada [50,51], but not during the 2011-2012 season in Canada [50].…”

Section: Expert Commentarymentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the health economic consequences of quadrivalent influenza vaccination

Boer

Maanen

Damm

et al. 2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

International audienceBackground: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B viruses. In this study, we systematically reviewed the available literature on health economic evaluations of switching from TIV to QIV.Areas covered: The databases of Medline and Embase were searched systematically to identify health economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies were included, thirteen cost-effectiveness analyses and three cost-comparisons.Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from TIV to QIV would be a valuable intervention from both the public health and economic viewpoint. However, more research seems mandatory. Our main recommendations for future research include: 1) more extensive use of dynamic models in order to estimate the full impact of QIV on influenza transmission including indirect effects, 2) improved availability of data on disease outcomes and costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and duration of protection

show abstract

“…It is not fully understood whether vaccination with one B lineage confers significant protection against the other. However, vaccine cross‐reactivity has been reported in adults 34, 35. Reduced vaccine effectiveness has been observed during seasons in which the vaccine B lineage does not match the circulating B lineage 36, 37.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of influenza B in Australia: 2001‐2014 influenza seasons

Moa

Muscatello

Turner

et al. 2016

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundInfluenza B is characterised by two antigenic lineages: B/Victoria and B/Yamagata. These lineages circulate together with influenza A during influenza seasons, with varying incidence from year to year and by geographic region.ObjectiveTo determine the epidemiology of influenza B relative to influenza A in Australia.MethodsLaboratory‐confirmed influenza notifications between 2001 and 2014 in Australia were obtained from the Australian National Notifiable Diseases Surveillance System.ResultsA total of 278 485 laboratory‐confirmed influenza cases were notified during the study period, comprising influenza A (82.2%), B (17.1%) and ‘other and untyped’ (0.7%). The proportion of notifications that were influenza B was highest in five‐ to nine‐year‐olds (27.5%) and lowest in persons aged 85 years and over (11.5%). Of all B notifications with lineage determined, 77.1% were B/Victoria and 22.9% were B/Yamagata infections. Mismatches between the dominant B lineage in a season and the trivalent vaccine B lineage occurred in over one‐third of seasons during the study years. In general, influenza B notifications peaked later than influenza A notifications.ConclusionThe proportion of circulating influenza B in Australia during 2001‐2014 was slightly lower than the global average and was dominated by B/Victoria. Compared with influenza A, influenza B infection was more common among older children and young adults and less common in the very elderly. Influenza B lineage mismatch with the trivalent vaccine occurred about one‐third of the time.

show abstract

Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials

Cited by 148 publications

References 57 publications

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

A systematic review of the health economic consequences of quadrivalent influenza vaccination

Epidemiology of influenza B in Australia: 2001‐2014 influenza seasons

Contact Info

Product

Resources

About